Tempest Therapeutics：公司同时探索将TPST-2003的潜在开发范围扩展至LBCL患者及其他相关适应症

美股速递02-25 21:02

Tempest Therapeutics Inc. 正在积极拓展其研发管线，公司目前正探索将核心候选药物TPST-2003的潜在开发计划延伸至淋巴瘤B细胞淋巴瘤（LBCL）患者群体，并覆盖其他相关适应症。这一战略动向显示出公司致力于挖掘该疗法在更广泛疾病领域中的应用潜力，旨在为更多患者提供新的治疗选择。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1171963738?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-02-25 21:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1171963738","market":"us","top_or_hot":-1,"title":"Tempest Therapeutics：公司同时探索将TPST-2003的潜在开发范围扩展至LBCL患者及其他相关适应症","media":"美股速递","content":"<p>Tempest Therapeutics Inc. 正在积极拓展其研发管线，公司目前正探索将核心候选药物TPST-2003的潜在开发计划延伸至淋巴瘤B细胞淋巴瘤（LBCL）患者群体，并覆盖其他相关适应症。这一战略动向显示出公司致力于挖掘该疗法在更广泛疾病领域中的应用潜力，旨在为更多患者提供新的治疗选择。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tempest Therapeutics：公司同时探索将TPST-2003的潜在开发范围扩展至LBCL患者及其他相关适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTempest Therapeutics：公司同时探索将TPST-2003的潜在开发范围扩展至LBCL患者及其他相关适应症\n</h2>\n\n<h4 class=\"meta\">\n\n2026-02-25 21:02 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tempest Therapeutics Inc. 正在积极拓展其研发管线，公司目前正探索将核心候选药物TPST-2003的潜在开发计划延伸至淋巴瘤B细胞淋巴瘤（LBCL）患者群体，并覆盖其他相关适应症。这一战略动向显示出公司致力于挖掘该疗法在更广泛疾病领域中的应用潜力，旨在为更多患者提供新的治疗选择。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TPST","symbol_name":"Tempest Therapeutics Inc.","start_time":0,"source_url":"","article_id":"1171963738","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1171963738","pubTimestamp":1772024532,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Tempest Therapeutics Inc. 正在积极拓展其研发管线，公司目前正探索将核心候选药物TPST-2003的潜在开发计划延伸至淋巴瘤B细胞淋巴瘤（LBCL）患者群体，并覆盖其他相关适应症。这一战略动向显示出公司致力于挖掘该疗法在更广泛疾病领域中的应用潜力，旨在为更多患者提供新的治疗选择。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"TPST":"Tempest Therapeutics Inc.","BK4139":"生物科技"},"translate_title":"Tempest Therapeutics: The company is also exploring the potential development scope of TPST-2003 to LBCL patients and other related indications","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TPST":1},"content_text":"Tempest Therapeutics Inc. 正在积极拓展其研发管线，公司目前正探索将核心候选药物TPST-2003的潜在开发计划延伸至淋巴瘤B细胞淋巴瘤（LBCL）患者群体，并覆盖其他相关适应症。这一战略动向显示出公司致力于挖掘该疗法在更广泛疾病领域中的应用潜力，旨在为更多患者提供新的治疗选择。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1171963738","isCrawlerRequest":true}